How will artificial intelligence and bioinformatics change our understanding of IgA Nephropathy in the next decade?
Roman David BülowDaniel DimitrovPeter BoorJulio Saez-RodriguezPublished in: Seminars in immunopathology (2021)
IgA nephropathy (IgAN) is the most common glomerulonephritis. It is characterized by the deposition of immune complexes containing immunoglobulin A (IgA) in the kidney's glomeruli, triggering an inflammatory process. In many patients, the disease has a progressive course, eventually leading to end-stage kidney disease. The current understanding of IgAN's pathophysiology is incomplete, with the involvement of several potential players, including the mucosal immune system, the complement system, and the microbiome. Dissecting this complex pathophysiology requires an integrated analysis across molecular, cellular, and organ scales. Such data can be obtained by employing emerging technologies, including single-cell sequencing, next-generation sequencing, proteomics, and complex imaging approaches. These techniques generate complex "big data," requiring advanced computational methods for their analyses and interpretation. Here, we introduce such methods, focusing on the broad areas of bioinformatics and artificial intelligence and discuss how they can advance our understanding of IgAN and ultimately improve patient care. The close integration of advanced experimental and computational technologies with medical and clinical expertise is essential to improve our understanding of human diseases. We argue that IgAN is a paradigmatic disease to demonstrate the value of such a multidisciplinary approach.
Keyphrases
- artificial intelligence
- big data
- machine learning
- deep learning
- single cell
- end stage renal disease
- ejection fraction
- endothelial cells
- healthcare
- multiple sclerosis
- chronic kidney disease
- high resolution
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- oxidative stress
- gene expression
- high throughput
- label free
- single molecule
- ulcerative colitis
- induced pluripotent stem cells
- circulating tumor